On the disclosed basis, 2025 revenue was KRW 251.7 billion and the operating loss was KRW 63.6 billion, an operating margin of -25.3%.
In the same year, net income attributable to controlling shareholders was KRW 85.3 billion and net income including non-controlling interests was also KRW 85.3 billion, so the operating loss and net profit moved in different directions.
Total equity at the end of 2025 was KRW 5.91 trillion and total liabilities were KRW 1.81 trillion, giving a debt ratio of 30.6%. Operating cash flow in 2025 was -KRW 103.7 billion.
Because the company was established in November 2025, the 2025 figures cover a partial post-establishment period and limit direct comparison with 2026. In Q1 2026, revenue was KRW 453.9 billion, operating profit KRW 90.5 billion and net income attributable to controlling shareholders KRW 99.5 billion.
In Q2, revenue fell to KRW 391.9 billion (down 13.7% from the prior quarter), operating profit to KRW 58.7 billion (down 35.1%) and controlling-shareholder net income to KRW 85.8 billion (down 13.7%).
In Q3, revenue rebounded to KRW 441.9 billion (up 12.8%), operating profit to KRW 105.1 billion (up 78.9%) and controlling-shareholder net income to KRW 96.3 billion (up 12.2%). Q3 operating profit exceeded the KRW 63.9 billion consensus compiled by Epic AI, while revenue was 8.0% below the KRW 480.1 billion consensus.
Cumulative January to September 2026 revenue reported on October 28, 2026 was KRW 1.29 trillion and operating profit was KRW 254.4 billion, a cumulative operating margin of 19.7%.
At subsidiary Samsung Bioepis, Q3 revenue was KRW 442.2 billion and operating profit KRW 132.6 billion, and excluding milestone income, product-sales operating profit rose 21.3% to KRW 106.9 billion.
Consolidated results at the holding level differ from the subsidiary's because of non-cash purchase accounting adjustments, including amortization of development costs from purchase price allocation.